The second pancrelipase formulation, which will be marketed as Viokace, has been approved in combination with a proton pump inhibitor for the treatment of exocrine pancreatic insufficiency from chronic pancreatitis or pancreatectomy 3 in adults.
Ultresa and Viokace are marketed by Aptalis Pharma U.S.